TORONTO — The U.S. Patent and Trademark Office has issued a patent covering Avicanna Inc.’s topical cannabinoid compositions for clear skin.
The issued patent, No. US 12,343,315 B2, covers a topical gel formulation that is comprised of cannabinoids in combination with antioxidants, anti-microbial agents, and anti-inflammatory agents and in reference to its potential in treating and preventing skin diseases and conditions including, but not limited to, acne, wrinkles, rosacea and erythema.
“We are delighted with the issuance of another USPTO patent as we continue to expand our intellectual property portfolio. We are excited about the potential of this patent that covers our composition that are in our commercial platforms and pharmaceutical pipeline.” stated Aras Azadian, CEO.
About Avicanna
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.
